Literature DB >> 27697755

Comparative Pharmacokinetic Profiling of Different Polymyxin B Components.

Pooja Manchandani1, Yanina Dubrovskaya2, Song Gao1, Vincent H Tam3,4.   

Abstract

Polymyxin B is increasingly used as a treatment of last resort for multidrug-resistant Gram-negative infections. Despite being available as a mixture of several structurally related analogues, the properties are commonly reported as an aggregate of the individual components. We compared the pharmacokinetics of individual polymyxin B components in an animal model and in humans. There were no considerable differences observed in the pharmacokinetics among major components of polymyxin B. Combining different components for pharmacokinetic analysis appeared reasonable.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27697755      PMCID： PMC5075123          DOI： 10.1128/AAC.00702-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Giao Vo; Samer Kabbara; Andrea L Kwa; Nathan P Wiederhold; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 2.  Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.

Authors:  Paschalis I Vergidis; Matthew E Falagas
Journal:  Curr Opin Investig Drugs       Date:  2008-02

3.  Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma.

Authors:  Vincent H Tam; Jingguo Hou; Andrea L Kwa; Randall A Prince
Journal:  J Antimicrob Chemother       Date:  2008-11-19       Impact factor: 5.790

4.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

5.  In vitro potency of various polymyxin B components.

Authors:  Vincent H Tam; Henry Cao; Kimberly R Ledesma; Ming Hu
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 6.  Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge?

Authors:  Daniel Curcio
Journal:  Curr Clin Pharmacol       Date:  2014-02

7.  Isolation and structural characterization of polymyxin B components.

Authors:  J A Orwa; C Govaerts; R Busson; E Roets; A Van Schepdael; J Hoogmartens
Journal:  J Chromatogr A       Date:  2001-04-06       Impact factor: 4.759

8.  Pharmacokinetics and renal disposition of polymyxin B in an animal model.

Authors:  Kamilia Abdelraouf; Jie He; Kimberly R Ledesma; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies.

Authors:  Jie He; Song Gao; Ming Hu; Diana S-L Chow; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2013-01-22       Impact factor: 5.790
  9 in total
  6 in total

1.  Critical Need for Clarity in Polymyxin B Dosing.

Authors:  Nikolas J Onufrak; Gauri G Rao; Alan Forrest; Jason M Pogue; Marc H Scheetz; Roger L Nation; Jian Li; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity.

Authors:  Pooja Manchandani; Jian Zhou; Jessica T Babic; Kimberly R Ledesma; Luan D Truong; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.

Authors:  Peile Wang; Qiwen Zhang; Zhenfeng Zhu; Hui Pei; Min Feng; Tongwen Sun; Jing Yang; Xiaojian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.

Authors:  Visanu Thamlikitkul; Yanina Dubrovskaya; Pooja Manchandani; Thundon Ngamprasertchai; Adhiratha Boonyasiri; Jessica T Babic; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 5.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 6.  A Review of the Clinical Pharmacokinetics of Polymyxin B.

Authors:  Sean N Avedissian; Jiajun Liu; Nathaniel J Rhodes; Andrew Lee; Gwendolyn M Pais; Alan R Hauser; Marc H Scheetz
Journal:  Antibiotics (Basel)       Date:  2019-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.